12/11
12:01 pm
fulc
Fulcrum Therapeutics (NASDAQ:FULC) was given a new $18.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Fulcrum Therapeutics (NASDAQ:FULC) was given a new $18.00 price target on by analysts at Truist Financial Corporation.
12/10
07:48 am
fulc
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
Medium
Report
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
12/9
01:15 pm
fulc
Fulcrum Therapeutics (NASDAQ:FULC) had its price target raised by analysts at Bank of America Corporation from $6.00 to $7.00. They now have an "underperform" rating on the stock.
Low
Report
Fulcrum Therapeutics (NASDAQ:FULC) had its price target raised by analysts at Bank of America Corporation from $6.00 to $7.00. They now have an "underperform" rating on the stock.
12/8
04:01 pm
fulc
Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock
High
Report
Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock
12/8
12:12 pm
fulc
Fulcrum Therapeutics (NASDAQ:FULC) was given a new $25.00 price target on by analysts at Stifel Nicolaus.
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) was given a new $25.00 price target on by analysts at Stifel Nicolaus.
12/8
11:02 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) had its "underperform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) had its "underperform" rating reaffirmed by analysts at Citigroup Inc..
12/8
10:13 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) had its "positive" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) had its "positive" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
12/8
09:14 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
12/8
09:14 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
12/8
08:07 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) had its price target raised by analysts at HC Wainwright from $18.00 to $25.00. They now have a "buy" rating on the stock.
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) had its price target raised by analysts at HC Wainwright from $18.00 to $25.00. They now have a "buy" rating on the stock.
12/8
07:03 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Low
Report
Fulcrum Therapeutics (NASDAQ:FULC) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
12/6
05:30 pm
fulc
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
High
Report
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
12/5
04:30 pm
fulc
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
High
Report
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/2
08:41 am
fulc
Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025 [Yahoo! Finance]
High
Report
Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025 [Yahoo! Finance]
12/2
08:30 am
fulc
Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025
High
Report
Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025
11/24
09:04 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) was given a new $14.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Fulcrum Therapeutics (NASDAQ:FULC) was given a new $14.00 price target on by analysts at Truist Financial Corporation.
11/24
08:43 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Low
Report
Fulcrum Therapeutics (NASDAQ:FULC) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
11/24
07:19 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/7
04:30 pm
fulc
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/3
04:45 pm
fulc
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
Medium
Report
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
10/30
11:02 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) had its price target raised by analysts at Royal Bank Of Canada from $5.00 to $7.00. They now have a "sector perform" rating on the stock.
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) had its price target raised by analysts at Royal Bank Of Canada from $5.00 to $7.00. They now have a "sector perform" rating on the stock.
10/30
08:13 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
10/29
07:00 am
fulc
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025
Medium
Report
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025
10/22
08:54 am
fulc
Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET
Medium
Report
Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET
10/21
06:01 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) was given a new $20.00 price target on by analysts at Leerink Partners. They now have an "outperform" rating on the stock.
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) was given a new $20.00 price target on by analysts at Leerink Partners. They now have an "outperform" rating on the stock.